{"name":"Neurim Pharmaceuticals Ltd.","slug":"neurim-pharmaceuticals-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Circadin","genericName":"Circadin","slug":"circadin","indication":"Disorders of initiating and maintaining sleep","status":"marketed"}]}],"pipeline":[{"name":"Circadin","genericName":"Circadin","slug":"circadin","phase":"marketed","mechanism":"Cytochrome P450 1B1, Myeloperoxidase, Nuclear receptor ROR-alpha","indications":["Disorders of initiating and maintaining sleep"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1id3RuZVYwTy1DT1V0VE91OThEZ0hYX05oUWw4SU1KbGpNd2xSei1iS1F3VWNNRHpuSmFhcWt3aVdrT2VwM3lncE9WYXJjZk1YejFpMWhHXzZWTUdMUEJfMnU0SkNWUUZmUHAtUlNSSklPZzA?oc=5","date":"2026-03-05","type":"trial","source":"Market Data Forecast","summary":"Insomnia Market Size, Growth & Trends, 2034 - Market Data Forecast","headline":"Insomnia Market Size, Growth & Trends, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxONGRwS1gwLUdNbDEzMHdxTGdrblFtQnM2aG1jTWJsVnVpYlN0a2tfQU1CMTh0OUpJRXlFU2JGaWJiSUp2VVpfWkRkbUlXZndXWGJGYWVHRTk4cmhJSzlQeGRBQkhPM0VvbmpmLUpPTl9CcHFMY292eFJsVTdCZHNKTjhaTXhfLW1LLU1wYk42c3hNZXV2TjdRZ3Y5bWphMTU5ZHRxZ0F2eHdFY0dkU3NFaDhlWXJoWlh2amJTOTdoNnNJa1ptN29Rb2lybHRvdXFJeXNzSTRrZEhrWV9XN3hKaFJ6WlI0RFNfTTdKWGdkcmFxV3ViOGRfd3kwamhkMGhr?oc=5","date":"2026-01-13","type":"pipeline","source":"newswire.ca","summary":"Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada - newswire.ca","headline":"Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE1FemFsajZSVmpwUm1Oa3c1M0QweDFLZHdOQU5JQUllQWNPV00wTWxaRTJERGdXbFQ0VnlOdUJKQVNCRnNRZEpBam1UbzNwSXF3THlqOEtWd2VhejQ?oc=5","date":"2025-07-27","type":"trial","source":"Being Patient","summary":"TRIALS UPDATE: The Latest Alzheimer’s Clinical Trial News (2025.02) - Being Patient","headline":"TRIALS UPDATE: The Latest Alzheimer’s Clinical Trial News (2025.02)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQTlh0QllQTVNwVWVCNG5kbmdiNC0tN3hkc3pwV1BjQTJTZl9UTUZuTTE0dUdwaXBUVzNTNTJncFdoWUY0dFRQeE5MbmwtNnNJYU1MeHdmTVYxZEhoM1pscG9wWHdwLVdlYlJ6VkJRaHJ5UUEzdDRJVFFZekR5T0V6dDhUcUd4dnpQMklpZHgybHBGcTdNYnh2N2w4bm9saS1Fcy1GNm5ibTBhOC1nanZoRkJnSHhuNmtkOXlVQWxKTDlCbXVKTW5SdWZibU1PQlZ3TXVZU0dfaGNzUHMtRHJLdA?oc=5","date":"2024-11-16","type":"pipeline","source":"www.hoganlovells.com","summary":"Court of Appeal grants Mylan stay of injunction pending appeal against validity of Neurim divisional - www.hoganlovells.com","headline":"Court of Appeal grants Mylan stay of injunction pending appeal against validity of Neurim divisional","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOcW9vX0FlX24wbXhuc2FBTFBOR1FCQWd3SGdoYWxJUURwZ1BmT1BDWFVLSHRoR21EVHl5LV9TOTAtaXlqaEI0WlNtX2FSeGtvOS1ZYlJhRnM0ZXpsMTlVQkdhWDkwR05IaXRjRktiVGRUeWNpX1hhUkFaS2NfcjJmdVNCX1FIX0NxdnRhT2diWW5UeXBvRGhNMnA3UQ?oc=5","date":"2024-08-30","type":"deal","source":"pearceip.law","summary":"Generic Partners & Apotex Infringe valid Neurim Sleep Patent - pearceip.law","headline":"Generic Partners & Apotex Infringe valid Neurim Sleep Patent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPSDBNRmU3YW4wUTlWV3J0NF8xYjNTWXNtS2JNMVFpcFJXTzVOOFktQUNmLVNSSFJnWGxrUFV5NF9CYlNkQXk3ckpmNnUycG15aDdxWHY4cHBkMkdOVG16UlRxSEdOeGw2elJqSkhtM3dWdWpNUGhyN0pUXzNzaTY1YUdVTWtnMXNPRFFiNVEwdzdQSEFTUVdTS1p4WmpaMHZSY3RzeEtrTlFydVRjeERodjJ0MENfOGJqYi1wbVgyRnZTTUh1UldGU0JYdHA?oc=5","date":"2023-08-22","type":"pipeline","source":"prnewswire.com","summary":"Sleep Aid Global Market to Surpass USD 50 Billion Mark by 2028 | DelveInsight - prnewswire.com","headline":"Sleep Aid Global Market to Surpass USD 50 Billion Mark by 2028 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPckk3UGhtSkpQWnRzYXpHTGcySVBmVVZKY096aEEza1ZVNm81QWktcjMyZ19fbTFYcmM5aE5PQ0hTS1NnM0thcUdKZ2VrSlJFZ3dtdWNqTkFWWVk3d1FFOVRDYzlRNzRZM214Zk9rTXpsUThsS0s0TzI5aEN5Q25RWm5sZkIxQjJ0ZFE?oc=5","date":"2022-05-30","type":"pipeline","source":"pearceip.law","summary":"“Method of” treating in the prior art not distinguishable from a “method for” treating - pearceip.law","headline":"“Method of” treating in the prior art not distinguishable from a “method for” treating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPSXJtNTdST3g0VGhEQjNuZWRIS3NnUWdoU0hJVUo2QnAtajhlVGxaRWdjb3lCV25RV3FNakNRTmJqbElPOU4yOGpYRGNPTTEzR3gxRmh4MVRteXJQaEl6b0U0UGtpYXNhWnZQdzU3WVRDRzVsX0VsekxhMENlcGlrcGZlN1VLc2NUUnEzcmNtV3I4NDNwWlBSV3NRZlhnUzM1NmZaNzJYRElSeFVoWnB6SEE0NE45QXNvN1E?oc=5","date":"2022-04-13","type":"deal","source":"Dechert","summary":"UK Court of Appeal rules on the rights of licensees to bring patent infringement claims - Dechert","headline":"UK Court of Appeal rules on the rights of licensees to bring patent infringement claims","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBQNnQwMkF4Y2Z6eTNucFIyUzBBUUFHSGFyVjNtNlpyTERFYUJpM3VGUWN2RlQxclptdUgwZmR4MENxbEV3bWx2ZzZ6eThmei03ME9odDgyWk9ReUlyelF2UDlBUVZUcURaeGlVcTFTaVZjNk1JNEdEanNYWElQdGM?oc=5","date":"2021-11-01","type":"pipeline","source":"Pharmacy Today","summary":"Circadin, now called Vigisom - Pharmacy Today","headline":"Circadin, now called Vigisom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxOSU13aWZBWE5tSmVfTnkxbXZVZ1Z3OGZqVkZmYmJRSjVMTFN2MVdGWXA3UWc3YlZDOG1pWDFtc2hNM1RFU1h4MDJzOXFIX0w1WFc2MmI5QTJod0dVcHBCU3pyOFZHcmRHNUttSWJZd01pTlp4TTBiMUhuaTFfMUJNVWVRMzI2dm1ua2FNZjZNZ2lMcF9XOTJqMlJxNzdZWmVfQnF0eF8wamJ6WG1aMHBrQUsyRmJmM2JINzBjcXlNYzRRQTU1ejlEQWpEb1V6T3dCeXZDSUNFYWlNSEktYUxRTFRUT1VhTGdvSmMzRjhjUzV0QTZ5UzF6czZnSS1GZVpIU2ZhUFFtRmZ5RWdFVEpQZmFRaXdPbXloMWlr?oc=5","date":"2020-06-26","type":"patent","source":"Herbert Smith Freehills Kramer","summary":"Court of Appeal of England & Wales maintains no interim injunction for Neurim and Flynn against generic Circadin® – damages held to be an adequate remedy - Herbert Smith Freehills Kramer","headline":"Court of Appeal of England & Wales maintains no interim injunction for Neurim and Flynn against generic Circadin® – dama","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQUGlGQ2ZVM0NmU1RJeHdmODZhVnVtT1NXSjhpZXZhOUpScGVrUkxWT2N0Q3MwV3V6U0VNMkkwbUlOa05rd1UzWE1HUHZzZ2lOdHhwMkt4ajFDcU5zVDNlb2pIWFBEd1A0c05qZ0s4S2Q3THRCNkc0ZTh4MWtEYndlT1o5Wmc4a3RpNDAyMi1majJGNGxmdkhqckQwaElWZDRhd1BjX29ldGFMWms4bjR5aUdHeUM1UHFZczZJUFRYemktckNpWEV1MTU4VGZhZEoxN0p6Q1pxU0RaYzdDN3pDNXdyUHZlYmpYbXIyQVludV9RVGhPLWFpODM0U2JoRGFtckY4b1d3UGRGRGZYVWFqYXdVaVJrMXhlVEFwZnFpQ0hvUWsxZURNcDRR?oc=5","date":"2020-06-11","type":"pipeline","source":"Herbert Smith Freehills Kramer","summary":"The rock misses its target in this story of “David and Goliath” – the UK High Court's consideration of interim injunctions in Neurim Pharmaceuticals v Mylan - Herbert Smith Freehills Kramer","headline":"The rock misses its target in this story of “David and Goliath” – the UK High Court's consideration of interim injunctio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOSDkwVFRlVl9jQzVxQ3BfTlRVdjZMb2dlOEhLbTNNRnZGNWRvd1V5RGNXZ0RiUElJSXEyajk4MHoxcE1nZW9KLWZMcW56ZENLZG8xVTBNWTAweHdIS3ZBOEZOVUZOeUl1bFlIUGxyMUlNUDkzQ2hydFZKYllxNWNhR1BmY3V4RURFR29wdXhNMlFuX0c3VkhxazBwTEUwN083REVWOE9aMDBnZkpKS01mZ0NXeDlSVXhXVW9ESnFXYkY1YVFsQjZhNi1lVjZHcWlTdVNjcUJFeGFzVWhFTlpobmVGSnJwSFZEbkJZbS04d2d0Yy1JX3d0clFZZTNrZ2M?oc=5","date":"2014-06-19","type":"pipeline","source":"prnewswire.com","summary":"Neurim Pharmaceuticals Announces Publication of Positive Effects of Add-on Circadin® in Alzheimer's Disease Patients - prnewswire.com","headline":"Neurim Pharmaceuticals Announces Publication of Positive Effects of Add-on Circadin® in Alzheimer's Disease Patients","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}